Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies - Disaggregation of Revenue (Details)

v3.19.1
Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)
1 Months Ended 12 Months Ended
Aug. 14, 2017
Aug. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]        
Revenues     $ 18,326,801 $ 27,813,137
Prescribed dietary supplements        
Disaggregation of Revenue [Line Items]        
Revenues     7,678,003 1,092,271
Prescription drugs        
Disaggregation of Revenue [Line Items]        
Revenues     10,192,742 818,132
License and other revenue        
Disaggregation of Revenue [Line Items]        
Revenues $ 25,000,000 $ 25,000,000 0 25,000,000
Sales force revenue        
Disaggregation of Revenue [Line Items]        
Revenues     456,056 278,165
Grant revenue        
Disaggregation of Revenue [Line Items]        
Revenues     $ 0 $ 624,569